All In Biotech

Drug Trial Radar · NCT02650804

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Jul 6, 2016

Primary completion

Jun 11, 2019

Study completion Jun 11, 2019

Sponsor

Lead sponsor
BPGbioIndustry
Sponsor type
Industry
First posted
Jan 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line therapy. The study will enroll up to 25 patients in the US and Europe.

Conditions

  • Pancreatic Cancer

Interventions

  • BPM31510 Nanosuspension InjectionDrug

  • GemcitabineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment ResponseTime frame: 10 weeks (End of Cycle 2)

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner Health

    Gilbert, Arizona

  • Mayo Clinic

    Phoenix, Arizona

  • Global Cancer Research Institute, Inc.

    Gilroy, California

  • Sarcoma Oncology Research Center

    Santa Monica, California

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Atlantic Health System Morristown Medical Center

    Morristown, New Jersey

  • Vita Medical Associates, P.C.

    Bethlehem, Pennsylvania

  • Mary Crowley Cancer Research Center

    Dallas, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • St Bartholomew's Hospital

    London, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

  • The Beatson West of Scotland Cancer Centre

    Glasgow, Strathclyde, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.